Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Petrelintide

Stage Phase 3

Sponsor Hoffmann-La Roche

Route injection

Class Amylin

Mechanism long-acting human amylin analogue

Sources

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07843485

Protocol section, NCT07843485 ZUPREME-4, last update posted 2026-11-05

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07843498

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 3900. Conditions Obesity or Overweight. This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, an

ClinicalTrials.gov NCT07843498 protocol and results modules

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT07843472

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 2500. Conditions Obesity or Overweight; Cardiovascular Disease. This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD)

ClinicalTrials.gov NCT07843472 protocol and results modules

registry, as of 2026-03-23Stale

https://clinicaltrials.gov/study/NCT06662539

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zealand Pharma. Enrollment 493. Conditions Obesity. The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

ClinicalTrials.gov NCT06662539 protocol and results modules

registry, as of 2026-09-09Stale

https://clinicaltrials.gov/study/NCT06926842

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2). Overall status COMPLETED. Phases PHASE2. Lead sponsor Zealand Pharma. Enrollment 221. Conditions Overweight; Type 2 Diabetes; Obesity. The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

ClinicalTrials.gov NCT06926842 protocol and results modules

registry, as of 2026-04-08Stale

https://clinicaltrials.gov/study/NCT07338214

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zealand Pharma. Enrollment 48. Conditions Obesity & Overweight. This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases. The goal is to learn how the same single dose of petrelintide, given using diff

ClinicalTrials.gov NCT07338214 protocol and results modules

publication, as of 2025-11-27Stale

https://pubmed.ncbi.nlm.nih.gov/41217931/

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. The past few years have seen the approval of several medications for weight management, but there is an increasing need for new therapies that target different pathways of energy

PMID 41217931

Studies

ZUPREME-4

Registry NCT07843485

Phase Phase 3

Status Recruiting

Enrollment 600

Start 2026-10-09

Primary completion 2028-10-20

Catalyst Primary completion. 2028-10-20

Petrelintide

Placebo

ZUPREME-3

Registry NCT07843498

Phase Phase 3

Status Recruiting

Enrollment 3900

Start 2026-09-30

Primary completion 2028-12-21

Study completion 2029-03-22

Catalyst Primary completion. 2028-12-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Petrelintide

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Placebo

Regimen once weekly

Population Obesity or Overweight

ZUPREME-5

Registry NCT07843472

Phase Phase 3

Status Recruiting

Enrollment 2500

Start 2026-09-30

Primary completion 2030-07-28

Study completion 2030-10-06

Catalyst Primary completion. 2030-07-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Petrelintide

Regimen once weekly

Comparator placebo

Population Obesity or Overweight; Cardiovascular Disease

Placebo

Regimen once weekly

Population Obesity or Overweight; Cardiovascular Disease

ZUPREME

Registry NCT06662539

EudraCT 2024-512549-18

Phase Phase 2

Status Completed

Enrollment 493

Start 2024-12-09

Primary completion 2025-09-30

Study completion 2026-03-07

Catalyst Primary completion. 2025-09-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Petrelintide Dose 1

Regimen once weekly

Comparator placebo

Population Obesity

Petrelintide Dose 2

Regimen once weekly

Comparator placebo

Population Obesity

Petrelintide Dose 3

Regimen once weekly

Comparator placebo

Population Obesity

Petrelintide Dose 4

Regimen once weekly

Comparator placebo

Population Obesity

Petrelintide Dose 5

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Registry NCT06926842

Phase Phase 2

Status Completed

Enrollment 221

Start 2025-04-22

Primary completion 2026-08-13

Study completion 2026-08-13

Catalyst Primary completion. 2026-08-13. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Treatment A: Petrelintide Dose 1

Regimen weekly

Comparator placebo

Population Overweight; Type 2 Diabetes; Obesity

Treatment B: Petrelintide Placebo Dose 1

Regimen weekly

Population Overweight; Type 2 Diabetes; Obesity

Treatment C: Petrelintide Dose 2

Regimen weekly

Comparator placebo

Population Overweight; Type 2 Diabetes; Obesity

Treatment D: Petrelintide Placebo Dose 2

Regimen weekly

Population Overweight; Type 2 Diabetes; Obesity

Treatment E: Petrelintide Dose 3

Regimen weekly

Comparator placebo

Population Overweight; Type 2 Diabetes; Obesity

Treatment F: Petrelintide Placebo Dose 3

Regimen weekly

Population Overweight; Type 2 Diabetes; Obesity

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Registry NCT07338214

Phase Phase 1

Status Completed

Enrollment 48

Start 2025-12-17

Primary completion 2026-03-31

Study completion 2026-03-31

Catalyst Primary completion. 2026-03-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm A

Population Obesity & Overweight

Arm B

Population Obesity & Overweight

Arm C

Population Obesity & Overweight

Arm D

Population Obesity & Overweight